SCHEMBL8173565

SCHEMBL8173565

O=C1NC(=S)S/C1=C\c1ccc(N(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAT1 P18440 5/20 0.75
CA2 P00918 1/20 0.75
EPHX1 P07099 1/20 0.75
CRHBP P24387 3/20 0.70
CRHR2 Q13324 3/20 0.70
MMP3 P08254 2/20 0.67
MMP13 P45452 2/20 0.67
MYC P01106 3/20 0.62
MAX P61244 2/20 0.62
CISD1 Q9NZ45 2/20 0.62
RAB9A P51151 2/20 0.62
NPC1 O15118 1/20 0.62
IL1RN P18510 1/20 0.62
ERAP1 Q9NZ08 1/20 0.62
GSK3B P49841 1/20 0.62
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
PIM1 P11309 1/20 0.60
POLB P06746 1/20 0.59
GPR35 Q9HC97 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8173568 1.00 NAT1 (0.75) NAT1CA2EPHX1CRHBPCRHR2
SCHEMBL4416451 0.86 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL3491175 0.86 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL1812224 0.86 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL10596480 0.84 NAT1 (1.00) NAT1CA2EPHX1CRHBPCRHR2
SCHEMBL1247510 0.84 NAT1 (1.00) NAT1CA2EPHX1CRHBPCRHR2
SCHEMBL1247509 0.84 NAT1 (1.00) NAT1CA2EPHX1CRHBPCRHR2
SCHEMBL8180288 0.83 XDH (0.67) NAT1CA2EPHX1CRHBPCRHR2
SCHEMBL8180287 0.83 XDH (0.67) NAT1CA2EPHX1CRHBPCRHR2
SCHEMBL194558 0.82 CRHBP (1.00) NAT1CA2EPHX1CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000018748-A1 RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 WO disclosed